Expanding Cold Chain Power to Meet Global Demand

Why It Matters

These initiatives give AFKLMP a competitive edge in the fast‑growing precision‑medicine market, where end‑to‑end visibility, regulatory compliance and low‑carbon transport are essential for patient outcomes and manufacturer expectations.

Key Takeaways

• AFKLMP Cargo converts CDG perishables cell into pharma‑only facility
• Real‑time global tracking system gives end‑to‑end visibility for shipments
• AI and predictive analytics anticipate temperature deviations and congestion risks
• Sustainable cool cells and SAF cut emissions while maintaining temperature control
• Collaboration with pharma makers and packaging firms fuels precision‑therapy logistics

Pulse Analysis

The surge in biologics, cell‑gene therapies and vaccine distribution has accelerated demand for reliable temperature‑controlled air cargo. Air France‑KLM‑Martinair Cargo (AFKLMP) is responding by expanding cold‑chain capacity at its European hubs, notably converting a perishables cool cell at Paris‑Charles‑de‑Gaulle into a dedicated pharmaceutical facility and adding similar assets at outstations where demand spikes. These infrastructure upgrades are paired with increased staffing and specialised handling processes that cater to time‑critical clinical trial shipments, ensuring the carrier can meet the faster‑than‑ever market growth.

Digitalisation sits at the core of AFKLMP’s strategy. A worldwide real‑time tracking platform now provides end‑to‑end visibility, while system‑to‑system booking links reduce manual paperwork and speed market entry for pharma customers. The carrier is also piloting AI‑driven predictive analytics that flag potential temperature excursions, congestion bottlenecks and container inefficiencies before they occur, shifting risk management from reactive to proactive. Combined with IATA CEIV Pharma and GDP certifications, these tools reinforce compliance across a fragmented regulatory landscape.

Sustainability and collaboration are shaping the next phase of pharma logistics. AFKLMP has introduced CO‑based cool cells that replace high‑global‑warming refrigerants and is expanding the use of Sustainable Aviation Fuel to lower Scope 3 emissions. Partnerships with pharmaceutical manufacturers, packaging innovators and industry consortia enable right‑sized, waste‑free containers and joint development of end‑to‑end logistics models for advanced therapies. By aligning network redundancy, digital insight and green initiatives, the carrier positions itself as a knowledge partner capable of supporting the projected double‑digit growth of precision‑medicine shipments over the coming decade.